NEEMA Web Tools
NEEMA supports development of a variety of web- and spreadsheet-based tools designed to provide state health policy makers and practitioners with information on local population sizes, disease trends, and cost projects for a variety of prevention strategies related to adolescent and school health, HIV, sexually transmitted diseases, tuberculosis and viral hepatitis.
An interactive webtool is now available for US states to estimate future US tuberculosis (TB) and latent TB infection (LTBI) cases based on a published TB transmission model. The tool, available at https://ppmltools.org/tabby2/external icon, provides projections based on state-specific historical trends, in addition to national projections based on national trends. Currently, 25 US states are modelled, with the remaining 25 states and the District of Columbia to be completed soon. Tabby2 allows users to choose pre-defined or to specify custom intervention scenarios to compare with baseline projections through 2050. The tool also allows users to estimate the number and cost of LTBI tests, LTBI treatments, and TB disease cases, as well as the cost effectiveness of hypothetical interventions. States can use Tabby2 to set informed targets to make a compelling case to further TB elimination.
Tabby directly reproduces numbers from Menzies et.al published in 2018. Tabby 2 updates the underlying data and adds functionality to predict TB in individual states. Both Tabby and Tabby 2 include predefined intervention scenarios to provide projections of TB trajectory. Custom hypothetical scenarios allow users to select health outcomes and population groups of interest and compare different scenarios.
Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA. Prospects for tuberculosis elimination in the United States: results of a transmission dynamic model.external icon. American Journal of Epidemiology. May 2018.
Learn more about Tabbyexternal icon and Tabby2external icon
Projecting impact of increased targeted testing and treatment on tuberculosis incidence among different high-risk populations in the four states: California, Florida, New York and Texas.
Shrestha S, Cherng S, Hill AN, Reynolds S, Flood J, Barry PM, Readhead A, Oxtoby M, Lauzardo M, Privett T, Marks SM. Impact and Effectiveness of State-level Tuberculosis interventions in California, Florida, New York and Texas: A model-based analysisexternal icon. American Journal of Epidemiology. 2019 Jun 28.
Displaying the state-level amount of “heterogeneity” of tuberculosis incidence for different high-risk populations.
Cherng ST, Shrestha S, Reynolds S, Hill AN, Marks SM, Kelly J, Dowdy DW. Tuberculosis Incidence Among Populations at High Risk in California, Florida, New York, and Texas, 2011–2015external icon. American Journal of Public Health. 2018 Nov;108(S4):S311-4.
Impact and cost-effectiveness of targeted testing and treatment (TTT) for latent tuberculosis infection (LTBI) among key populations in the four most populous US states.
Jo Y, Shrestha S, Gomes I, Marks S, Hill A, Asay G, Dowdy D. Model-based cost-effectiveness of state-level tuberculosis interventions in California, Florida, New York, and Texas. Under review.
Estimate the number of individuals indicated for PrEP.
Smith DK, Van Handel M, Grey J. Estimates of Persons with Indications for Preexposure Prophylaxis by Jurisdiction Transmission Risk Group, and Race/Ethnicity, United States, 2015external icon. Annals of Epidemiology, 2018.
This Excel-based tool is designed to assist health departments in estimating the short-term impact of behavior change on the burden of sexually transmitted infections among adolescents in their jurisdictions.
Creation of web tools was supported by the US Centers for Disease Control and Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (NEEMA) PS14-1415.
The Hep C State Policy Simulator (the Simulator) is a tool to help state heath policy makers and practitioners make decisions regarding policy, strategy, and investments related to hepatitis C. The Simulator was developed by Mass General Hospital and Harvard Medical School with support from CDC through a cooperative agreement awarded to ChangeLab Solutions.
Creation of Hep C State Policy Simulator was supported by the US Centers for Disease Control and Prevention through a Cooperative Agreement number NU38OT000141.
